



HEXAGON NUTRITION LIMITED

Nutritionally Yours...

Ref: HNL/SEC/2026-27/17

Date: 12th August 2026

To,

National Stock Exchange of India Limited

Listing & Compliance Department

Exchange Plaza, C-1, Block G,

Bandra Kurla Complex,

Bandra (East), Mumbai – 400051

Maharashtra, India.

SYMBOL: HEXAGON

BSE Limited

Listing Department

Floor 25, P J Towers,

Dalal Street, Mumbai – 400001

Maharashtra, India.

Scrip Code: 544785

Re: HEXAGON NUTRITION LIMITED - ISIN: INE0JUI01012

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on Wednesday, August 12, 2026 and Disclosures under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

This is to inform you that the Board of Directors of the Company at their meeting held on Wednesday, August 12, 2026 at 4.15 pm at the registered office of the Company situated at 404, Global Chamber, Adarsh Nagar, Link Road, Andheri (W), Mumbai – 400053, Maharashtra, India, inter alia, transacted the following businesses:

1. Approved the unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026, and took on record the Limited Review Report issued by the Statutory Auditors thereon (copy enclosed herewith as **Annexure-I**).

Further, the Quick Response (QR) Code and the details of the webpage where the complete financial results, i.e. the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, are available, shall also be published in the newspapers in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. Convening of the 33rd (Thirty-Third) Annual General Meeting ("AGM") of the Members of the Company on Tuesday, September 22, 2026 at 11:30 a.m., through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM") as may be applicable. The Book closure for the purpose of the AGM shall be from 16th September 2026 to 22nd September 2026.
3. Recommended a final dividend of ₹ 0.30 Paise per Equity Share of face value of ₹1/- each for the financial year ended March 31, 2026, and fixed Tuesday, September 15, 2026, as the Record Date for determining the eligibility of Members to receive the aforesaid final dividend, if declared by the Members at the ensuing Annual General Meeting.

CIN:- L24110MH1993PLC072189

Registered Office :

404 Global Chamber, Adarsh Nagar, Link Road,
Andheri (W), Mumbai, Maharashtra - 400053, India

Tel. No.: +91-22-62136710/711

Website : www.hexagonnutrition.com

Email ID: enquiry@hexagonnutrition.com

HNL-075

Nashik Plant :

Plot No. 92 & Plot No. 447, Unandanagar, Lakhamapur,
Dindori, Nasik - 422 202, Maharashtra, India

Chennai Plant :

Plot No. B11 Phase - 1 MEPZ-SEZ, Tambaram,
Chennai - 600 045, Tamil Nadu, India

Tel. No.: +91-44-22625252

Email ID: infochennai@hexagonnutrition.com

4. Approved revision in the annual remuneration payable to the following Directors, subject to approval of members at the Annual General Meeting: -
 - a) Mr. Arun Purushottam Kelkar (DIN: 00171276), Chairman and Executive Director
 - b) Mr. Vikram Arun Kelkar (DIN: 02302364), Managing Director
 - c) Dr. Nikhil Arun Kelkar (DIN: 02302369), Joint Managing Director of the Company.
5. Recommended Re-appointment of Mr. Arun Purushottam Kelkar (DIN: 00171276) as Chairman & Director of the Company, subject to the approval of the Members of the Company. The requisite disclosures relating to the Re- appointment of Mr. Arun Purushottam Kelkar pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as **Annexure II**.
6. Appointment of Mr. Raghunath Sawant as an Additional Executive Director of the Company w.e.f. 12th August 2026. The requisite disclosures relating to the appointment of Mr. Raghunath Sawant pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as **Annexure II**.
7. The alteration of the Articles of Association of the Company, subject to the members approval the requisite disclosures pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as **Annexure III**.
8. Approved the dissolution of the IPO Committee with immediate effect after successful completion of the IPO.

The Board Meeting commenced at 04:15 P.M. and concluded at 06:15 P.M.

Also, pursuant to the Company's Code of Conduct for Prevention of Insider Trading and the SEBI (Prohibition of Insider Trading) Regulations, 2015, 'Trading Window' for all Directors, Promoters, Connected Persons, Designated Persons and their immediate relatives of the Company, for trading in the shares of the Company shall be open after 48 hours of declaration of Financial Results of the company for the quarter ended June 30, 2026.

The same will be made available on the Company's website, i.e. <https://hexagonnutrition.com/>.

Kindly take the above on record.

Yours faithfully,
For Hexagon Nutrition Limited

Vedanti Vartak
Company Secretary and Compliance Officer
ICSI Membership No.: A41580

S K Patodia & Associates LLP

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Quarterly Consolidated Unaudited Financial Results of Hexagon Nutrition Limited pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Hexagon Nutrition Limited

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Hexagon Nutrition Limited, ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation").
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Holding Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following wholly owned subsidiaries:

Sr. No.	Name of the Entity	Country/ Region
1	Hexagon Nutrition (International) Private Limited	India
2	Hexagon Nutrition Healthcare Private Limited	India
3	Hexagon Nutrition Proprietary Ltd.	South Africa
4	Hexagon Nutrition LLC	Uzbekistan
5	Hexagon Nutrition China Ltd.	Hong Kong

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Registered Office : Unit No. 202, 2nd Floor, Sumer Plaza, Marol, Andheri (East), Mumbai - 400 059
Tel.: +91 22 6958 6482 | Email : info@skpatodia.in | Website : www.skpatodia.in

(LLP Identification No : ACE - 4113)

(S K Patodia & Associates (a partnership firm) converted into S K Patodia & Associates LLP with effect from December 15, 2023)

Emphasis of Matter

6. We draw attention to Note 4 to the accompanying consolidated financial results, which describes the merger of Hexagon Nutrition (Exports) Private Limited, an erstwhile wholly owned subsidiary of the Company, with Hexagon Nutrition Limited, the Holding Company.
7. We draw attention to Note 5 to the accompanying consolidated financial results, which describes the conversion of the Holding Company's Compulsorily Convertible Preference Shares (CCPS) into equity shares on April 20, 2026.
8. We draw attention to Note 6 to the accompanying consolidated financial results, which describes the listing of the Holding Company's equity shares on the stock exchanges on June 12, 2026.
9. We draw attention to Note 7 to the accompanying consolidated financial results, which describes the matters relating to two foreign subsidiaries of the Company, Hexagon Nutrition Proprietary Ltd and Hexagon Nutrition LLC, that indicate the existence of a material uncertainty which may cast significant doubt on their ability to continue as a going concern.

Our conclusion is not modified with respect to these matters.

Other Matters

10. The accompanying statement also includes the Group's share of total income (including other income) of ₹83.96 million, net profit / (loss) after tax of ₹(7.91) million, and total comprehensive income / (loss) of ₹(12.19) million for the quarter ended June 30, 2026, in respect of three subsidiaries located outside India, as considered in the statement, based on their interim financial statements / financial information / financial results which have not been reviewed by their auditors, and are certified by the Management.
11. The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the consolidated audited figures in respect of the full financial year ended on March 31, 2026 and the audited year-to-date figures for the nine months ended December 31, 2025.
12. The Statement includes the consolidated results for the corresponding quarter ended June 30, 2025 which have not been subject to review or audit by us and are presented solely based on the information compiled by the management and have been approved by the Board of Directors. Refer Note 9 to the accompanying Consolidated financial results.

Our conclusion is not modified with respect to these matters.

For S K Patodia & Associates LLP

Chartered Accountants

Firm Registration Number: 112723W /W100962



Dhiraj Lalpuria

Partner

Membership Number: 146268

UDIN: 26146268JELTZT6108

Place: Mumbai

Date: August 12, 2026



HEXAGON NUTRITION LIMITED

CIN : L24110MH1993PLC072189


Registered Office : 404, Global Chamber, Adarsh Nagar, Link Road, Andheri (W), Mumbai-400053

WEBSITE : www.hexagonnutrition.com, Email : cs.hnpl@hexagonnutrition.com

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(All amounts in Rupees millions, unless otherwise stated)

Particulars	Quarter Ended			Year Ended
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	Unaudited	Audited (Refer Note 9)	Unaudited (Refer Notes 4 & 9)	Audited (Refer Note 4)
A. FINANCIAL PERFORMANCE				
1 Income				
(a) Revenue from Operations	1,043.06	1,150.41	728.61	3,826.28
(b) Other Income	20.78	39.55	13.76	119.38
Total Income	1,063.84	1,189.96	742.37	3,945.66
2 Expenses				
(a) Cost of materials consumed	670.86	552.68	426.15	2,024.69
(b) Purchases of stock-in-trade	12.55	-	36.75	2.55
(c) Changes in inventories of Finished Goods and Work - in- progress	(98.37)	93.07	(75.72)	(31.87)
(d) Employee benefits expense	136.11	144.19	110.97	504.38
(e) Finance Costs	9.82	11.29	7.97	40.22
(f) Depreciation and Amortisation Expense	22.96	27.49	21.68	96.40
(g) Other expenses	204.52	209.95	130.01	800.55
Total Expenses	958.45	1,038.67	657.81	3,436.92
3 Profit/(Loss) before exceptional items and tax (1-2)	105.39	151.29	84.56	508.74
4 Exceptional Items - (Income)/Expenses	(0.62)	(2.98)	(0.15)	(3.06)
5 Profit/(Loss) before tax (3-4)	106.01	154.27	84.71	511.80
6 Tax Expense				
(a) Current Tax	37.90	43.76	19.92	133.58
(b) Deferred Tax	(12.62)	1.47	0.24	(1.15)
Total Tax Expense	25.28	45.23	20.16	132.43
7 Net Profit/(Loss) for the period (5-6)	80.73	109.04	64.55	379.37
8 Other Comprehensive Income				
A(i) Items that will not be reclassified to profit or loss				
Remeasurement of post employment benefit obligation	0.92	4.38	(0.22)	9.89
(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.26)	(1.11)	0.06	(2.49)
B(i) Items that will be reclassified to profit or loss				
Exchange differences in translating the financial statements of foreign operations	2.95	4.35	2.98	4.35
Total Other Comprehensive Income	3.61	7.62	2.82	11.75
9 Total Comprehensive Income for the period/year (7+8)	84.34	116.66	67.37	391.12
Profit for the period/year (A)				
Owners of the Company	80.73	109.04	64.55	379.37
Non-Controlling Interest	-	-	-	-
Other comprehensive income (OCI) (B)				
Owners of the Company	3.61	7.62	2.82	11.75
Non-Controlling Interest	-	-	-	-
Total comprehensive income for the period/year (A+B)				
Owners of the Company	84.34	116.66	67.37	391.12
Non-Controlling Interest	-	-	-	-
10 Paid up Equity Share Capital (Face Value of Rs. 1/- each) (Refer Note 5)	122.92	110.63	110.63	110.63
11 Other Equity excluding Revaluation Reserves				2,222.30
12 Earnings Per Equity Share of face value of Rs. 1/- (not annualised)				
Basic (Rs.) (Refer Note 5)	0.67	0.99	0.58	3.43
Diluted (Rs.)	0.66	0.89	0.53	3.09
See accompanying notes to the consolidated unaudited financial results				



HEXAGON NUTRITION LIMITED
CIN : L24110MH1993PLC072189

Registered Office : 404, Global Chamber, Adarsh Nagar, Link Road, Andheri (W), Mumbai-400053
WEBSITE : www.hexagonnutrition.com, Email : cs.hnpl@hexagonnutrition.com

Notes

- 1 The above consolidated unaudited financial results of Hexagon Nutrition Limited (the "Holding Company") and its subsidiaries (together referred to as the "Group") have been reviewed and recommended by the audit committee and approved by the Board of Directors of the Company in their respective meetings held on 12th August, 2026. Further the limited review of the consolidated unaudited financial results for the quarter ended 30th June, 2026 in terms of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended time to time, has been carried out by the statutory auditor of the Holding Company.
- 2 The above consolidated unaudited financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013 ("the Act") read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).
- 3 The Board of Directors of the Holding Company, at its meeting held on 12th August 2026, has recommended a Final Dividend of ₹0.30 per equity share of face value of ₹1.00 each for the financial year ended 31st March 2026.

The recommended final dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM). In accordance with Ind AS 10 (Events After the Reporting Period) and Ind AS 34 (Interim Financial Reporting), this recommendation is a non-adjusting event occurring after the end of the quarter ended 30th June 2026. Accordingly, no liability has been recognized in the consolidated unaudited financial results for the quarter ended 30th June 2026, and the dividend will be accounted for in the period in which it is approved by the shareholders.

- 4 The Board of Directors at their meeting held on March 19, 2025, considered and approved to restructure the business by way of a Scheme of Amalgamation for merger ("Scheme") where by the wholly owned subsidiary M/s. Hexagon Nutrition (Exports) Private Limited ("Transferor Company") will be merged into the Parent Company M/s. Hexagon Nutrition Limited ("Transferee Company"). Subsequently, an application was made on May 10, 2025 to the National Company Law Tribunal (NCLT) and received approval on January 14, 2026 Vide Order No C.P.(CAA)/225(MB)2025 C.A.(CAA)/141 (MB)2025 with appointed date of the scheme is April 01, 2025.

The amalgamation has been accounted for under the Pooling of Interests Method in accordance with Appendix C to Ind AS 103 – Business Combinations.

Accordingly, the consolidated unaudited financial results for the comparative periods have been restated as if the amalgamation had occurred from the beginning of the earliest period presented, in accordance with the provisions of the Scheme. Therefore, the comparative figures presented in these consolidated unaudited financial results are not directly comparable with the financial information previously reported for those periods.

- 5 During the quarter ended 30th June 2026, the Holding Company converted its outstanding Compulsorily Convertible Preference Shares (CCPS) into Equity Shares of face value of ₹1/- each, in accordance with the terms of the investment agreement and the conversion ratio approved by the Board.

Consequently, the paid-up equity share capital of the Holding Company stands increased from the said date.

There is no impact of this conversion on the financial numbers or profitability of the Group for the quarter ended 30th June 2026, except for the impact on Earnings Per Share (EPS).

- 6 During the quarter ended 30th June 2026, the Holding Company completed its Initial Public Offering (IPO) through a 100% Offer for Sale (OFS) of 3,08,59,704 equity shares of face value of ₹1/- each at an offer price of ₹45/- per share, aggregating to ₹138.87 crores by the existing selling shareholders.

The equity shares of the Company were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 12th June 2026.

Since the issue was entirely an Offer for Sale, the Holding Company did not receive any proceeds from the IPO. All eligible share issue expenses are being recovered from the selling shareholders in accordance with the offer agreements, and there is no impact on the financial position or profitability of the Holding Company for the quarter ended 30th June 2026.



HEXAGON NUTRITION LIMITED

CIN : L24110MH1993PLC072189

Registered Office : 404, Global Chamber, Adarsh Nagar, Link Road, Andheri (W), Mumbai-400053

WEBSITE : www.hexagonnutrition.com, Email : cs.hnpl@hexagonnutrition.com

Notes

- 7 As of 31 March 2026, the financial statements of the subsidiary entities, Hexagon Nutrition Proprietary Ltd (HNPTY) South Africa and Hexagon Nutrition LLC (HNLLC) Uzbekistan, reflect a net liability position amounting to Rs. (121.91) million due to historical accumulated losses. The Management has initiated robust strategic interventions aimed at reviving business performance, enhancing revenue streams, and optimizing cost structures across these overseas operations.

The long-term sustainability remains subject to regional market dynamics, presenting a material uncertainty regarding future cash flows. To mitigate this risk, the Holding Company has committed to provide unconditional financial support, guaranteeing to fund all future liabilities and operational obligations as and when they fall due. Consequently, given this definitive backing and the current operational trajectory, management retains a reasonable expectation of the entities' long-term viability, and these financial results have been prepared on a Going Concern basis.

- 8 In accordance with Ind AS 108- Operating Segments, the Group operates in a single business segment i.e "manufacturing of nutritional products".

- 9 The figures of the last quarter are the balancing figures between consolidated audited figures in respect of the full financial year and the consolidated audited year to date figures up to the third quarter of the respective financial year. Also, the figures for the quarter ended 30 June 2025, as reported in these consolidated unaudited financial results have been approved by the Board of Directors, but have not been subjected to any review or audit by the statutory auditors since the requirement of submission of quarterly reviewed financial results only became applicable on listing of equity shares of the Holding Company, which was from the quarter ended 31 March 2026.

- 10 Subsequent to the quarter ended June 30, 2026, the Holding Company initiated the phased decommissioning and operational restructuring of its Premix manufacturing facility located at Nashik, Maharashtra. In accordance with Ind AS 10 (Events After the Reporting Period) and Ind AS 34 (Interim Financial Reporting), this event occurred after the reporting date and represents a non-adjusting event; accordingly, it has no financial impact on the results for the quarter ended June 30, 2026.

The financial impact—including PPE derecognition, impairment/disposal assessment, and net salvage realization—is currently under evaluation and will be recognized in subsequent accounting periods as the restructuring progresses. (The same was disclosed in the Offer Document/Prospectus of the Company).

- 11 The above results are also being made available on the Stock Exchange websites www.nseindia.com and www.bseindia.com and on the company's website www.hexagonnutrition.com

- 12 Previous year/ period figures have been regrouped/ reclassified/ rearranged/ recast wherever necessary.



For and on behalf of Board of Directors of
Hexagon Nutrition Limited


Vikram Kelkar
Managing Director
DIN : 02302364



Place : Mumbai
Date : 12th August 2026

S K Patodia & Associates LLP

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Quarterly Standalone Unaudited Financial Results of Hexagon Nutrition Limited pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Hexagon Nutrition Limited

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Hexagon Nutrition Limited, ("the Company") for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

5. We draw attention to Note 5 to the accompanying standalone financial results, which describes the conversion of the Company's Compulsorily Convertible Preference Shares (CCPS) into equity shares on April 20, 2026.
6. We draw attention to Note 4 to the accompanying standalone financial results, which describes the merger of Hexagon Nutrition (Exports) Private Limited, an erstwhile wholly owned subsidiary of the Company, with Hexagon Nutrition Limited, the Holding Company.
7. We draw attention to Note 6 to the accompanying standalone financial results, which describes the listing of the Company's equity shares on the stock exchanges on June 12, 2026.

Our conclusion is not modified with respect to these matters.



Registered Office : Unit No. 202, 2nd Floor, Sumer Plaza, Marol, Andheri (East), Mumbai - 400 059
Tel.: +91 22 6958 6482 | Email : info@skpatodia.in | Website : www.skpatodia.in

(LLP Identification No : ACE - 4113)

(S K Patodia & Associates (a partnership firm) converted into S K Patodia & Associates LLP with effect from December 15, 2023)

Other Matters

8. The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited standalone figures in respect of the full financial year ended on March 31, 2026 and the audited year-to-date figures for the nine months ended December 31, 2025.
9. The Statement includes the standalone results for the corresponding quarter ended June 30, 2025 which have not been subject to review or audit by us and are presented solely based on the information compiled by the management and have been approved by the Board of Directors. Refer Note 8 to the accompanying standalone financial results.

Our conclusion is not modified with respect to these matters.

For S K Patodia & Associates LLP
Chartered Accountants
Firm Registration Number: 112723W /W100962



Dhiraj Lalpuria
Partner
Membership Number: 146268
UDIN: 26146268DPMSGF1889

Place: Mumbai
Date: August 12, 2026



HEXAGON NUTRITION LIMITED
CIN : L24110MH1993PLC072189

Registered Office : 404, Global Chamber, Adarsh Nagar, Link Road, Andheri (W), Mumbai-400053

WEBSITE : www.hexagonnutrition.com, Email : cs.hnpl@hexagonnutrition.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(All amounts in Rupees millions, unless otherwise stated)

Particulars	Quarter Ended			Year Ended
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	Unaudited	Audited (Refer Note 8)	Unaudited (Refer Notes 4 & 8)	Audited (Refer Note 4)
A. FINANCIAL PERFORMANCE				
1 Income				
(a) Revenue from Operations	1,014.02	984.71	632.57	3,191.20
(b) Other Income	29.64	61.50	21.07	152.14
Total Income	1,043.66	1,046.21	653.65	3,343.34
2 Expenses				
(a) Cost of materials consumed	603.05	504.92	361.60	1,705.74
(b) Purchases of stock-in-trade	12.55	-	-	2.55
(c) Changes in inventories of finished goods, work-in-progress	(15.06)	21.16	(24.32)	(44.99)
(d) Employee benefits expense	119.76	127.76	97.61	444.86
(e) Finance Costs	6.67	6.24	4.01	18.82
(f) Depreciation and Amortisation Expense	14.29	16.46	13.44	57.44
(g) Other expenses	170.63	190.89	121.60	650.05
Total Expenses	911.89	867.43	573.95	2,834.47
3 Profit/(Loss) before exceptional items and tax (1-2)	131.77	178.78	79.70	508.87
4 Exceptional Items - (Income)/Expenses	(0.62)	(3.20)	(0.16)	(3.56)
5 Profit/(Loss) before tax (3-4)	132.39	181.98	79.86	512.43
6 Tax Expense				
(a) Current Tax	37.90	45.51	19.92	133.03
(b) Deferred Tax	(3.85)	0.14	0.25	(2.08)
Total Tax Expense	34.05	45.65	20.17	130.95
7 Net Profit/(Loss) for the period/year (5-6)	98.34	136.33	59.69	381.48
8 Other Comprehensive Income				
(i) Items that will not be reclassified to profit or loss				
Remeasurement of post employment benefit obligation	0.92	4.35	(0.22)	9.51
(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.28)	(1.09)	0.06	(2.39)
Total Other Comprehensive Income	0.64	3.26	(0.16)	7.12
9 Total Comprehensive Income/(Loss) for the period (7+8)	98.98	139.59	59.53	388.60
10 Paid up Equity Share Capital (Face Value Rs. 1/- each) (Refer Note 5)	122.92	110.63	110.63	110.63
11 Other Equity excluding Revaluation Reserves				2,202.73
12 Earnings Per Equity Share of face value of Rs. 1/- (not annualised)				
Basic (Rs.) (Refer Note 5)	0.82	1.23	0.54	3.45
Diluted (Rs.)	0.80	1.11	0.49	3.10
See accompanying notes to the standalone unaudited financial results				



HEXAGON NUTRITION LIMITED

CIN : L24110MH1993PLC072189

Registered Office : 404, Global Chamber, Adarsh Nagar, Link Road, Andheri (W), Mumbai-400053

WEBSITE : www.hexagonnutrition.com, Email : cs.hnpl@hexagonnutrition.com

Notes

- ¹ The above standalone unaudited financial results of Hexagon Nutrition Limited (the "Company") have been reviewed and recommended by the audit committee and approved by the Board of Directors of the Company in their respective meetings held on 12th August, 2026. Further the limited review of the standalone unaudited financial results for the quarter ended 30th June, 2026 in terms of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended time to time, has been carried out by the statutory auditor of the Company.
- 2 The above standalone unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013 ("the Act") read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).
- 3 The Board of Directors of the Company, at its meeting held on 12th August 2026, has recommended a Final Dividend of ₹0.30 per equity share of face value of ₹1.00 each for the financial year ended 31st March 2026.

The recommended final dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM). In accordance with Ind AS 10 (Events After the Reporting Period) and Ind AS 34 (Interim Financial Reporting), this recommendation is a non-adjusting event occurring after the end of the quarter ended 30th June 2026. Accordingly, no liability has been recognized in the standalone unaudited financial results for the quarter ended 30th June 2026, and the dividend will be accounted for in the period in which it is approved by the shareholders.

- 4 The Board of Directors at their meeting held on March 19, 2025, considered and approved to restructure the business by way of a Scheme of Amalgamation for merger ("Scheme") where by the wholly owned subsidiary M/s. Hexagon Nutrition (Exports) Private Limited ("Transferor Company") will be merged into the Parent Company M/s. Hexagon Nutrition Limited ("Transferee Company"). Subsequently, an application was made on May 10, 2025 to the National Company Law Tribunal (NCLT) and received approval on January 14, 2026 Vide Order No C.P.(CAA)/225(MB)2025 C.A.(CAA)/141 (MB)2025 with appointed date of the scheme is April 01, 2025.

The amalgamation has been accounted for under the Pooling of Interests Method in accordance with Appendix C to Ind AS 103 – Business Combinations.

Accordingly, the standalone unaudited financial results for the comparative periods have been restated as if the amalgamation had occurred from the beginning of the earliest period presented, in accordance with the provisions of the Scheme. Therefore, the comparative figures presented in these standalone unaudited financial results are not directly comparable with the financial information previously reported for those periods.

- 5 During the quarter ended 30th June 2026, the Company converted its outstanding Compulsorily Convertible Preference Shares (CCPS) into Equity Shares of face value of ₹1/- each, in accordance with the terms of the investment agreement and the conversion ratio approved by the Board.

Consequently, the paid-up equity share capital of the Company stands increased from the said date.

There is no impact of this conversion on the financial numbers or profitability of the Company for the quarter ended 30th June 2026, except for the impact on Earnings Per Share (EPS).



HEXAGON NUTRITION LIMITED

CIN : L24110MH1993PLC072189

Registered Office : 404, Global Chamber, Adarsh Nagar, Link Road, Andheri (W), Mumbai-400053

WEBSITE : www.hexagonnutrition.com, Email : cs.hnpl@hexagonnutrition.com


Notes

- 6 During the quarter ended 30th June 2026, the Company completed its Initial Public Offering (IPO) through a 100% Offer for Sale (OFS) of 3,08,59,704 equity shares of face value of ₹1/- each at an offer price of ₹45/- per share, aggregating to ₹138.87 crores by the existing selling shareholders.
The equity shares of the Company were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 12th June 2026.
Since the issue was entirely an Offer for Sale, the Company did not receive any proceeds from the IPO. All eligible share issue expenses are being recovered from the selling shareholders in accordance with the offer agreements, and there is no impact on the financial position or profitability of the Company for the quarter ended 30th June 2026.
- 7 In accordance with Ind AS 108- Operating Segments, the company operates in a single business segment i.e "manufacturing of nutritional products".
- 8 The figures of the last quarter are the balancing figures between standalone audited figures in respect of the full financial year and the standalone audited year to date figures up to the third quarter of the respective financial year. Also, the figures for the quarter ended 30 June 2025, as reported in these standalone unaudited financial results have been approved by the Board of Directors, but have not been subjected to any review or audit by the statutory auditors since the requirement of submission of quarterly reviewed financial results only became applicable on listing of equity shares of the Company, which was from the quarter ended 31 March 2026.
- 9 Subsequent to the quarter ended June 30, 2026, the Company initiated the phased decommissioning and operational restructuring of its Premix manufacturing facility located at Nashik, Maharashtra. In accordance with Ind AS 10 (Events After the Reporting Period) and Ind AS 34 (Interim Financial Reporting), this event occurred after the reporting date and represents a non-adjusting event; accordingly, it has no financial impact on the results for the quarter ended June 30, 2026.
The financial impact—including PPE derecognition, impairment/disposal assessment, and net salvage realization—is currently under evaluation and will be recognized in subsequent accounting periods as the restructuring progresses. (The same was disclosed in the Offer Document/Prospectus of the Company).
- 10 The above results are also being made available on the Stock Exchange websites www.nseindia.com and www.bseindia.com and on the company's website www.hexagonnutrition.com
- 11 Previous year/ period figures have been regrouped/ reclassified/ rearranged/ recast wherever necessary.

For and on behalf of Board of Directors of

Hexagon Nutrition Limited




Vikram Kelkar
Managing Director
DIN : 02302364



Place : Mumbai

Date : 12th August 2026

ANNEXURE – II

Details as per SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026

Sr. No	Particulars	Details	Details
1	Name of the Director/ Key managerial personnel (KMP)	Mr. Raghunath Sawant (DIN- 11863172)	Mr. Arun Purushottam Kelkar (DIN: 00171276)
2	Designation	Additional Executive Director	Chairman & Executive Director
3	Reason for change viz. appointment, re- appointment, resignation, removal, death or otherwise;	Appointment	Reappointment
4	Date of appointment/ reappointment and term of appointment	12 th August 2026 for 5 years liable to retire by rotation	28 th September 2026 for 5 years
5	Brief Profile	He has been associated with the company as an employee since July 20, 2022. He holds a Diploma in Food Technology from Maharashtra State Board of Technical Education	Mr. Arun Purushottam Kelkar is the Chairman and Executive Director of our Company. He holds a bachelor's degree in Engineering from Nagpur University. He has also completed Diploma in Operations Management from University of Mumbai. He has been associated with our Company since its incorporation.
6	Disclosure of relationship between Directors	NA	Promoter of the Company. He is the father of Dr. Nikhil Kelkar, Joint Managing Director and Mr. Vikram Kelkar, Managing Director of the Company.

ANNEXURE – III

Details with respect to alteration of the Articles of Association of the Company required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026

Sr. No	Details
1	The proposed alteration primarily provides for: (a) deletion of Part B of the Articles of Association in its entirety; and (b) removal of references to Malani Ventures Private Limited and its affiliates appearing in the Articles of Association.